PL3186192T3 - Białko fuzyjne, nanocząstka zbudowana z wielu monomerów wspomnianego białka fuzyjnego oraz ich zastosowanie - Google Patents

Białko fuzyjne, nanocząstka zbudowana z wielu monomerów wspomnianego białka fuzyjnego oraz ich zastosowanie

Info

Publication number
PL3186192T3
PL3186192T3 PL15791743T PL15791743T PL3186192T3 PL 3186192 T3 PL3186192 T3 PL 3186192T3 PL 15791743 T PL15791743 T PL 15791743T PL 15791743 T PL15791743 T PL 15791743T PL 3186192 T3 PL3186192 T3 PL 3186192T3
Authority
PL
Poland
Prior art keywords
fusion protein
monomers
nanoparticle composed
nanoparticle
fusion
Prior art date
Application number
PL15791743T
Other languages
English (en)
Inventor
Pierpaolo CECI
Elisabetta FALVO
Original Assignee
Thena Biotech S.r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thena Biotech S.r.l. filed Critical Thena Biotech S.r.l.
Publication of PL3186192T3 publication Critical patent/PL3186192T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/001159—Matrix metalloproteinases [MMP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15791743T 2014-09-30 2015-09-29 Białko fuzyjne, nanocząstka zbudowana z wielu monomerów wspomnianego białka fuzyjnego oraz ich zastosowanie PL3186192T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO20140779 2014-09-30
EP15791743.6A EP3186192B1 (en) 2014-09-30 2015-09-29 A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof
PCT/IB2015/057448 WO2016051340A1 (en) 2014-09-30 2015-09-29 A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof

Publications (1)

Publication Number Publication Date
PL3186192T3 true PL3186192T3 (pl) 2018-07-31

Family

ID=51904166

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15791743T PL3186192T3 (pl) 2014-09-30 2015-09-29 Białko fuzyjne, nanocząstka zbudowana z wielu monomerów wspomnianego białka fuzyjnego oraz ich zastosowanie

Country Status (11)

Country Link
US (1) US10640775B2 (pl)
EP (1) EP3186192B1 (pl)
JP (1) JP6745795B2 (pl)
CN (1) CN106922149B (pl)
CA (1) CA2963053C (pl)
DK (1) DK3186192T3 (pl)
ES (1) ES2665218T3 (pl)
PL (1) PL3186192T3 (pl)
PT (1) PT3186192T (pl)
RU (1) RU2714155C2 (pl)
WO (1) WO2016051340A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109422799B (zh) * 2017-08-22 2022-07-29 复旦大学 多烯紫杉醇抗肝癌靶向前药及其药用用途
PT3707261T (pt) * 2017-11-06 2022-07-13 Thena Biotech S R L Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos
CN108707618B (zh) * 2018-05-16 2022-04-08 华南农业大学 一种基于人铁蛋白的纳米酶及其制备方法
CN112912385A (zh) * 2018-10-29 2021-06-04 味之素株式会社 包封有有机化合物的铁蛋白的制造方法
WO2021008454A1 (zh) * 2019-07-12 2021-01-21 昆山新蕴达生物科技有限公司 基于铁蛋白重链亚基的药物载体
CN111203546B (zh) * 2020-01-21 2021-08-17 中国农业大学 一种十六聚体铁蛋白-金纳米簇及其制备方法
WO2021251358A1 (ja) * 2020-06-09 2021-12-16 味の素株式会社 修飾フェリチンおよびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
EP3138581B1 (en) * 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
US20140121127A1 (en) * 2012-10-31 2014-05-01 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Diagnosis of Ovarian Cancer
CN104013599B (zh) * 2014-05-28 2016-11-23 中国科学院生物物理研究所 一种肿瘤特异性靶向给药的药物载体及其应用

Also Published As

Publication number Publication date
CN106922149B (zh) 2021-11-23
US20170298364A1 (en) 2017-10-19
JP6745795B2 (ja) 2020-08-26
CA2963053A1 (en) 2016-04-07
PT3186192T (pt) 2018-04-09
WO2016051340A1 (en) 2016-04-07
ES2665218T3 (es) 2018-04-24
RU2017114673A3 (pl) 2019-04-25
DK3186192T3 (en) 2018-04-23
JP2017532958A (ja) 2017-11-09
CA2963053C (en) 2024-01-23
US10640775B2 (en) 2020-05-05
EP3186192A1 (en) 2017-07-05
RU2017114673A (ru) 2018-11-02
CN106922149A (zh) 2017-07-04
RU2714155C2 (ru) 2020-02-12
EP3186192B1 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
HK1255067A1 (zh) 抗c10orf54抗體及其用途
IL304772A (en) Antibodies, uses and methods
HK1243440A1 (zh) 抗白細胞介素-33抗體及其用途
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
EP3200812B8 (en) Novel alpha4beta7 peptide monomer and dimer antagonists
EP3111310A4 (en) Zone grouping
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
PL3186192T3 (pl) Białko fuzyjne, nanocząstka zbudowana z wielu monomerów wspomnianego białka fuzyjnego oraz ich zastosowanie
IL252430A0 (en) Antibodies, uses and methods
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
IL247590A0 (en) Bispecific antibodies and their uses
GB201408673D0 (en) Medicaments,uses and methods
GB201513819D0 (en) Polymers, and methods for their production
GB201405784D0 (en) Novel methods, polypeptides and uses thereof
SG11201606501PA (en) Nanobody-fluorescent protein fusion
IL251518A0 (en) Astaxanthin-based polymers and their uses
IL249897A0 (en) 2-oxo-4,3-dihydropyridine-5-carboxylates and their use
GB201406705D0 (en) Fusion proteins,polynucleotides,expression vectors, and their uses
GB201411605D0 (en) Polymer, method of making a polymer and uses of said polymer